Table 2.
In vivo efficacy of nemonoxacin and the reference compound in mouse systemic infection
| Organism | Challenge dose (CFU/mouse) | Nemonoxacin
|
Levofloxacin
|
P-value | ||
|---|---|---|---|---|---|---|
| MIC (mg/L) | ED50 (95% CI) (mg/kg) | MIC (mg/L) | ED50 (95% CI) (mg/kg) | |||
| S. aureus, ATCC 29213 (MSSA) | 2.1 × 105 | 0.03 | 2.08 (1.68–2.59) | 0.125 | 5.02 (4.02–6.25) | <0.01 |
| S. aureus 0705 (MRSA) | 2.5 × 105 | 0.03 | 2.59 (2.24–2.98) | 0.25 | 8.45 (7.60–9.41) | <0.01 |
| S. capitis 0687 (levofloxacin-resistant MRSC) | 8.8 × 104 | 0.5 | 2.52 (2.17–2.93) | 8 | 4.32 (3.96–4.72) | <0.01 |
| S. pneumonia ATCC 49619 (PISP) | 8.8 × 105 | 0.125 | 5.47 (4.55–6.57) | 1 | 19.14 (16.98–21.57) | <0.01 |
| S. pneumonia 0518 (PRSP) | 2.2 × 105 | 0.25 | 3.68 (3.11–4.36) | 2 | 19.82 (17.57–22.37) | <0.01 |
| S. pneumonia 0613 (PRSP) | 1.8 × 105 | 0.25 | 5.28 (4.21–6.62) | 2 | 22.01 (19.50–24.83) | <0.01 |
| E. faecalis ATCC 29212 | 3.3 × 106 | 0.03 | 15.16 (12.64–18.17) | 0.5 | 26.89 (23.25–31.09) | <0.01 |
| E. faecalis 4041 (VRE) | 1.1 × 108 | 0.06 | 8.48 (6.88–10.45) | 1 | 17.47 (14.18–21.53) | <0.01 |
| E. coli ATCC 25922 | 6.0 × 105 | 0.03 | 3.13 (2.40–4.10) | 0.015 | 0.68 (0.56–0.83) | <0.01 |
| E. coli 0635 | 1.5 × 105 | 0.06 | 3.28 (2.85–4.01) | 0.015 | 0.97 (0.85–1.12) | <0.01 |
| E. coli 0638 | 1.0 × 105 | 0.06 | 5.28 (4.58–6.09) | 0.015 | 0.84 (0.73–0.96) | <0.01 |
Note: Data from Li et al.18
Abbreviations: ED50, 50% effective dose; ATCC, American Type Culture Collection (ATCC), Manassas, VA, USA; CFU, colony-forming units; MIC, minimum inhibitory concentration; CI, confidence interval; MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; MRSC, methicillin-resistant S. capitis; PISP, penicillin-intermediate S. pneumoniae; PRSP, penicillin-resistant S. pneumoniae; VRE, vancomycin-resistant Enterococcus.